Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mengist, Hylemariam Mihiretie, Mekonnen, Daniel, Mohammed, Ahmed, Shi, Ronghua, Jin, Tengchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883113/
https://www.ncbi.nlm.nih.gov/pubmed/33597888
http://dx.doi.org/10.3389/fphar.2020.630500
_version_ 1783651176452980736
author Mengist, Hylemariam Mihiretie
Mekonnen, Daniel
Mohammed, Ahmed
Shi, Ronghua
Jin, Tengchuan
author_facet Mengist, Hylemariam Mihiretie
Mekonnen, Daniel
Mohammed, Ahmed
Shi, Ronghua
Jin, Tengchuan
author_sort Mengist, Hylemariam Mihiretie
collection PubMed
description Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 M(pro) are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 M(pro) and forward directions on the development of future studies focusing on COVID-19 therapeutics.
format Online
Article
Text
id pubmed-7883113
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78831132021-02-16 Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease Mengist, Hylemariam Mihiretie Mekonnen, Daniel Mohammed, Ahmed Shi, Ronghua Jin, Tengchuan Front Pharmacol Pharmacology Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 M(pro) are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 M(pro) and forward directions on the development of future studies focusing on COVID-19 therapeutics. Frontiers Media S.A. 2021-02-01 /pmc/articles/PMC7883113/ /pubmed/33597888 http://dx.doi.org/10.3389/fphar.2020.630500 Text en Copyright © 2021 Mengist, Mekonnen, Mohammed, Shi and Jin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mengist, Hylemariam Mihiretie
Mekonnen, Daniel
Mohammed, Ahmed
Shi, Ronghua
Jin, Tengchuan
Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_full Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_fullStr Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_full_unstemmed Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_short Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_sort potency, safety, and pharmacokinetic profiles of potential inhibitors targeting sars-cov-2 main protease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883113/
https://www.ncbi.nlm.nih.gov/pubmed/33597888
http://dx.doi.org/10.3389/fphar.2020.630500
work_keys_str_mv AT mengisthylemariammihiretie potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease
AT mekonnendaniel potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease
AT mohammedahmed potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease
AT shironghua potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease
AT jintengchuan potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease

Ejemplares similares